MediciNova, Inc.

NASDAQ:MNOV

Biotechnology

Healthcare
$1.33 -1.32%

-$0.02 today

Market cap
$68.14M
Beta
0.62
P/E (TTM)
-5.6
EPS (TTM)
-$0.24
52W Low $1.17High $1.96

Volume 0.12M

Average 0.04M

MNOV Pre-Tax Margin

Income before tax as a percentage of revenue.

MediciNova, Inc.NASDAQ: MNOV

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin at -1383.1%

Pre-tax margin was -1383.1% in Q1 FY2026. On a trailing-twelve-month basis it was -1963.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-1383.1%+459.7 pp QoQ
Last fiscal yearDec 2025
-2927.3%— YoY
LTMMar 2026
-1963.3%— YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-2927.3%
Year-over-year change
—

Pre-Tax Margin vs competitors

How MNOV compares with its peers on the latest reported figures

  • MNOV's LTM Mar 2026 pre-tax margin of -1963.3% is the 4th highest of the 5 companies compared; the peer median is -673.0%.
MNOV Competitors Peer median
Pre-Tax Margin for MNOV and competitors
Company Period LTM level YoY 3-year change
FBIOFortress Biotech, Inc.LTM Mar 2026201.4% +385.1 pp+228.8 pp
VXRTVaxart, Inc.LTM Mar 202614.7% +136.7 pp+100652.9 pp
TCRXTScan Therapeutics, Inc.LTM Mar 2026-1360.6% +1613.5 pp-767.6 pp
MNOVMediciNova, Inc.LTM Mar 2026-1963.3% ——
CBUSCibus, Inc.LTM Mar 2026-2426.4% +3995.7 pp+7126.5 pp
RLMDRelmada Therapeutics, Inc.FY2025— ——
IMUXImmunic, Inc.FY2025— ——
PMVPPMV Pharmaceuticals, Inc.FY2025— ——
ACRVAcrivon Therapeutics, Inc. Common StockFY2025— ——
XBITXBiotech Inc.FY2025— ——
BMEABiomea Fusion, Inc.FY2025— ——
Peer median (excluding MNOV) -673.0%+999.3 pp+3677.7 pp

Competitors are the stored peer set for MNOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.04M01M0409.66K
Cost of Revenue0000378.61K
Gross Profit4.04M01M031.05K
Gross Margin100.0%—100.0%—7.6%
Research & Development8.1M9.14M5.66M7.2M7.15M
Selling, General & Admin5.72M5.48M5.24M5.48M6.16M
Operating Expenses14.25M14.63M10.9M12.68M13.31M
Depreciation & Amortization26.15K17.71K20.3K21.08K20.1K
EBITDA(10.11M)(14.05M)(8.55M)(11.02M)(11.97M)
EBITDA Margin-250.3%—-854.8%—-2922.4%
Operating Income(10.22M)(14.63M)(9.9M)(12.68M)(13.28M)
Operating Margin-253.0%—-990.0%—-3242.5%
Interest Income143.63K809.67K1.83M1.67M1.3M
Interest Expense00000
Other Income / Expenses84.13K562.39K1.33M1.63M1.29M
Income Before Tax(10.13M)(14.07M)(8.57M)(11.04M)(11.99M)
Pre-Tax Margin-250.9%—-856.8%—-2927.3%
Income Tax Expense2.57K2.82K3.05K5.54K5.99K
Net Income(10.13M)(14.07M)(8.57M)(11.05M)(12M)
Net Margin-251.0%—-857.2%—-2928.8%
EPS (Basic)(0.21)(0.29)(0.17)(0.23)(0.24)
EPS (Diluted)(0.21)(0.29)(0.17)(0.23)(0.24)
Weighted Avg Shares48.6M49.05M49.05M49.05M49.06M
Weighted Avg Shares (Diluted)48.6M49.05M49.05M49.05M49.06M

MediciNova, Inc.

NASDAQ:MNOV

Intrinsic Alpha fair value

Locked

Current Price

$1.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.